{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,28]],"date-time":"2026-08-28T08:21:44Z","timestamp":1787905304068,"version":"build-2784847793"},"reference-count":46,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,8,28]]},"DOI":"10.7759\/cureus.115334","type":"journal-article","created":{"date-parts":[[2026,8,28]],"date-time":"2026-08-28T07:57:35Z","timestamp":1787903855000},"source":"Crossref","is-referenced-by-count":0,"title":["Efficacy and Safety of Biologic Therapies Targeting Type 2 and Epithelial-Alarmin Pathways in Chronic Obstructive Pulmonary Disease: A Systematic Review and Network Meta-Analysis of Randomized Controlled Trials"],"prefix":"10.7759","author":[{"given":"Yasser A","family":"Khoshaim","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ahmad R","family":"Almaghrabi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ahmed A","family":"Alruwaythi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abdulkhaliq E","family":"Alotaibi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ibrahim M","family":"Alhoshan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Talal A","family":"Almalki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abdullah A","family":"Sabbah","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abdullah W","family":"Al-Shuaibi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Osama N","family":"Almarzoqi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"OBai T","family":"Mesawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alwaleed","family":"Alabdali","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1016\/S2213-2600(21)00511-7","article-title":"Global, regional, and national prevalence of, and risk factors for, chronic obstructive pulmonary disease (COPD) in 2019: a systematic review and modelling analysis","volume":"10","author":"Adeloye D","year":"2022","unstructured":"Adeloye D, Song P, Zhu Y, Campbell H, Sheikh A, Rudan I. Global, regional, and national prevalence of, and risk factors for, chronic obstructive pulmonary disease (COPD) in 2019: a systematic review and modelling analysis. Lancet Respir Med. 2022, 10:447-58. 10.1016\/S2213-2600(21)00511-7","journal-title":"Lancet Respir Med"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1016\/S2213-2600(17)30293-X","article-title":"Global, regional, and national deaths, prevalence, disability-adjusted life years, and years lived with disability for chronic obstructive pulmonary disease and asthma, 1990-2015: a systematic analysis for the Global Burden of Disease Study 2015","volume":"5","author":"Soriano JB","year":"2017","unstructured":"Soriano JB, Abajobir AA, Abate KH, et al.. Global, regional, and national deaths, prevalence, disability-adjusted life years, and years lived with disability for chronic obstructive pulmonary disease and asthma, 1990-2015: a systematic analysis for the Global Burden of Disease Study 2015. Lancet Respir Med. 2017, 5:691-706. 10.1016\/S2213-2600(17)30293-X","journal-title":"Lancet Respir Med"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1164\/rccm.202303-0455CI","article-title":"Targeting type 2 inflammation and epithelial alarmins in chronic obstructive pulmonary disease: a biologics outlook","volume":"208","author":"Rabe KF","year":"2023","unstructured":"Rabe KF, Rennard S, Martinez FJ, et al.. Targeting type 2 inflammation and epithelial alarmins in chronic obstructive pulmonary disease: a biologics outlook. Am J Respir Crit Care Med. 2023, 208:395-405. 10.1164\/rccm.202303-0455CI","journal-title":"Am J Respir Crit Care Med"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1183\/23120541.00437-2020","article-title":"Targeted therapy in eosinophilic chronic obstructive pulmonary disease","volume":"7","author":"Fieldes M","year":"2021","unstructured":"Fieldes M, Bourguignon C, Assou S, et al.. Targeted therapy in eosinophilic chronic obstructive pulmonary disease. ERJ Open Res. 2021, 7:00437-2020. 10.1183\/23120541.00437-2020","journal-title":"ERJ Open Res"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1183\/13993003.00239-2023","article-title":"Global Initiative for Chronic Obstructive Lung Disease 2023 report: GOLD executive summary","volume":"61","author":"Agust\u00ed A","year":"2023","unstructured":"Agust\u00ed A, Celli BR, Criner GJ, et al.. Global Initiative for Chronic Obstructive Lung Disease 2023 report: GOLD executive summary. Eur Respir J. 2023, 61:2300239. 10.1183\/13993003.00239-2023","journal-title":"Eur Respir J"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1136\/thorax.57.10.847","article-title":"Relationship between exacerbation frequency and lung function decline in chronic obstructive pulmonary disease","volume":"57","author":"Donaldson GC","year":"2002","unstructured":"Donaldson GC, Seemungal TA, Bhowmik A, Wedzicha JA. Relationship between exacerbation frequency and lung function decline in chronic obstructive pulmonary disease. Thorax. 2002, 57:847-52. 10.1136\/thorax.57.10.847","journal-title":"Thorax"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1136\/thoraxjnl-2011-201518","article-title":"Long-term natural history of chronic obstructive pulmonary disease: severe exacerbations and mortality","volume":"67","author":"Suissa S","year":"2012","unstructured":"Suissa S, Dell'Aniello S, Ernst P. Long-term natural history of chronic obstructive pulmonary disease: severe exacerbations and mortality. Thorax. 2012, 67:957-63. 10.1136\/thoraxjnl-2011-201518","journal-title":"Thorax"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1111\/cts.13899","article-title":"Dupilumab: mechanism of action, clinical, and translational science","volume":"17","author":"McCann MR","year":"2024","unstructured":"McCann MR, Kosloski MP, Xu C, Davis JD, Kamal MA. Dupilumab: mechanism of action, clinical, and translational science. Clin Transl Sci. 2024, 17:e13899. 10.1111\/cts.13899","journal-title":"Clin Transl Sci"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1080\/17476348.2020.1718495","article-title":"Antibodies targeting the interleukin-5 signaling pathway used as add-on therapy for patients with severe eosinophilic asthma: a review of the mechanism of action, efficacy, and safety of the subcutaneously administered agents, mepolizumab and benralizumab","volume":"14","author":"Hillas G","year":"2020","unstructured":"Hillas G, Fouka E, Papaioannou AI. Antibodies targeting the interleukin-5 signaling pathway used as add-on therapy for patients with severe eosinophilic asthma: a review of the mechanism of action, efficacy, and safety of the subcutaneously administered agents, mepolizumab and benralizumab. Expert Rev Respir Med. 2020, 14:353-65. 10.1080\/17476348.2020.1718495","journal-title":"Expert Rev Respir Med"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejim.2024.05.011","article-title":"Towards precision medicine in COPD: targeting type 2 cytokines and alarmins","volume":"125","author":"Varricchi G","year":"2024","unstructured":"Varricchi G, Poto R. Towards precision medicine in COPD: targeting type 2 cytokines and alarmins. Eur J Intern Med. 2024, 125:28-31. 10.1016\/j.ejim.2024.05.011","journal-title":"Eur J Intern Med"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1016\/S2213-2600(15)00106-X","article-title":"Blood eosinophil counts, exacerbations, and response to the addition of inhaled fluticasone furoate to vilanterol in patients with chronic obstructive pulmonary disease: a secondary analysis of data from two parallel randomised controlled trials","volume":"3","author":"Pascoe S","year":"2015","unstructured":"Pascoe S, Locantore N, Dransfield MT, Barnes NC, Pavord ID. Blood eosinophil counts, exacerbations, and response to the addition of inhaled fluticasone furoate to vilanterol in patients with chronic obstructive pulmonary disease: a secondary analysis of data from two parallel randomised controlled trials. Lancet Respir Med. 2015, 3:435-42. 10.1016\/S2213-2600(15)00106-X","journal-title":"Lancet Respir Med"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1186\/s12931-019-1268-7","article-title":"Blood eosinophil count, a marker of inhaled corticosteroid effectiveness in preventing COPD exacerbations in post-hoc RCT and observational studies: systematic review and meta-analysis","volume":"21","author":"Harries TH","year":"2020","unstructured":"Harries TH, Rowland V, Corrigan CJ, et al.. Blood eosinophil count, a marker of inhaled corticosteroid effectiveness in preventing COPD exacerbations in post-hoc RCT and observational studies: systematic review and meta-analysis. Respir Res. 2020, 21:3. 10.1186\/s12931-019-1268-7","journal-title":"Respir Res"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1007\/s40265-026-02303-3","article-title":"GOLD 2026: transforming COPD management with early intervention, multi-dimensional assessment, and personalized care","volume":"86","author":"Cazzola M","year":"2026","unstructured":"Cazzola M, Bajpai J, Calzetta L, Matera MG, Rogliani P. GOLD 2026: transforming COPD management with early intervention, multi-dimensional assessment, and personalized care. Drugs. 2026, 86:581-97. 10.1007\/s40265-026-02303-3","journal-title":"Drugs"},{"key":"ref14","unstructured":"Dupilumab (Dupixent) for COPD. (2025). Accessed. August 20, 2026: https:\/\/secure.medicalletter.org\/TML-article-1720c."},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2034975","article-title":"Tezepelumab in adults and adolescents with severe, uncontrolled asthma","volume":"384","author":"Menzies-Gow A","year":"2021","unstructured":"Menzies-Gow A, Corren J, Bourdin A, et al.. Tezepelumab in adults and adolescents with severe, uncontrolled asthma. N Engl J Med. 2021, 384:1800-9. 10.1056\/NEJMoa2034975","journal-title":"N Engl J Med"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1080\/15412555.2025.2449889","article-title":"Biologic therapies for chronic obstructive pulmonary disease: a systematic review and network meta-analysis of randomized controlled trials","volume":"22","author":"Pitre T","year":"2025","unstructured":"Pitre T, Lupas D, Mah J, Stanbrook M, Blazer A, Zeraatkar D, Ho T. Biologic therapies for chronic obstructive pulmonary disease: a systematic review and network meta-analysis of randomized controlled trials. COPD. 2025, 22:2449889. 10.1080\/15412555.2025.2449889","journal-title":"COPD"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2413181","article-title":"Mepolizumab to prevent exacerbations of COPD with an eosinophilic phenotype","volume":"392","author":"Sciurba FC","year":"2025","unstructured":"Sciurba FC, Criner GJ, Christenson SA, et al.. Mepolizumab to prevent exacerbations of COPD with an eosinophilic phenotype. N Engl J Med. 2025, 392:1710-20. 10.1056\/NEJMoa2413181","journal-title":"N Engl J Med"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(26)00637-9","article-title":"Safety and efficacy of astegolimab for COPD with frequent exacerbations regardless of baseline blood eosinophil counts (ALIENTO and ARNASA): randomised, double-blind, placebo-controlled, phase 2b and 3 trials","volume":"407","author":"Papi A","year":"2026","unstructured":"Papi A, Singh D, Virchow JC, et al.. Safety and efficacy of astegolimab for COPD with frequent exacerbations regardless of baseline blood eosinophil counts (ALIENTO and ARNASA): randomised, double-blind, placebo-controlled, phase 2b and 3 trials. Lancet. 2026, 407:2027-39. 10.1016\/S0140-6736(26)00637-9","journal-title":"Lancet"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.1183\/13993003.02231-2024","article-title":"A phase 2a trial of the IL-33 monoclonal antibody tozorakimab in patients with COPD: FRONTIER-4","volume":"66","author":"Singh D","year":"2025","unstructured":"Singh D, Guller P, Reid F, et al.. A phase 2a trial of the IL-33 monoclonal antibody tozorakimab in patients with COPD: FRONTIER-4. Eur Respir J. 2025, 66:2402231. 10.1183\/13993003.02231-2024","journal-title":"Eur Respir J"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.n71","article-title":"The PRISMA 2020 statement: an updated guideline for reporting systematic reviews","volume":"372","author":"Page MJ","year":"2021","unstructured":"Page MJ, McKenzie JE, Bossuyt PM, et al.. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ. 2021, 372:n71. 10.1136\/bmj.n71","journal-title":"BMJ"},{"key":"ref21","doi-asserted-by":"publisher","DOI":"10.7326\/M14-2385","article-title":"The PRISMA extension statement for reporting of systematic reviews incorporating network meta-analyses of health care interventions: checklist and explanations","volume":"162","author":"Hutton B","year":"2015","unstructured":"Hutton B, Salanti G, Caldwell DM, et al.. The PRISMA extension statement for reporting of systematic reviews incorporating network meta-analyses of health care interventions: checklist and explanations. Ann Intern Med. 2015, 162:777-84. 10.7326\/M14-2385","journal-title":"Ann Intern Med"},{"key":"ref22","doi-asserted-by":"publisher","DOI":"10.1186\/s13643-020-01542-z","article-title":"PRISMA-S: an extension to the PRISMA statement for reporting literature searches in systematic reviews","volume":"10","author":"Rethlefsen ML","year":"2021","unstructured":"Rethlefsen ML, Kirtley S, Waffenschmidt S, Ayala AP, Moher D, Page MJ, Koffel JB. PRISMA-S: an extension to the PRISMA statement for reporting literature searches in systematic reviews. Syst Rev. 2021, 10:39. 10.1186\/s13643-020-01542-z","journal-title":"Syst Rev"},{"key":"ref23","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.l4898","article-title":"RoB 2: a revised tool for assessing risk of bias in randomised trials","volume":"366","author":"Sterne JA","year":"2019","unstructured":"Sterne JA, Savovi\u0107 J, Page MJ, et al.. RoB 2: a revised tool for assessing risk of bias in randomised trials. BMJ. 2019, 366:l4898. 10.1136\/bmj.l4898","journal-title":"BMJ"},{"key":"ref24","doi-asserted-by":"publisher","DOI":"10.1002\/jrsm.1411","article-title":"Risk-of-bias VISualization (robvis): an R package and Shiny web app for visualizing risk-of-bias assessments","volume":"12","author":"McGuinness LA","year":"2021","unstructured":"McGuinness LA, Higgins JP. Risk-of-bias VISualization (robvis): an R package and Shiny web app for visualizing risk-of-bias assessments. Res Synth Methods. 2021, 12:55-61. 10.1002\/jrsm.1411","journal-title":"Res Synth Methods"},{"key":"ref25","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1905248","article-title":"Benralizumab for the prevention of COPD exacerbations","volume":"381","author":"Criner GJ","year":"2019","unstructured":"Criner GJ, Celli BR, Brightling CE, et al.. Benralizumab for the prevention of COPD exacerbations. N Engl J Med. 2019, 381:1023-34. 10.1056\/NEJMoa1905248","journal-title":"N Engl J Med"},{"key":"ref26","doi-asserted-by":"publisher","DOI":"10.1016\/S2213-2600(24)00324-2","article-title":"Efficacy and safety of tezepelumab versus placebo in adults with moderate to very severe COPD (COURSE): a randomised, placebo-controlled, phase 2a trial","volume":"13","author":"Singh D","year":"2025","unstructured":"Singh D, Brightling CE, Rabe KF, et al.. Efficacy and safety of tezepelumab versus placebo in adults with moderate to very severe COPD (COURSE): a randomised, placebo-controlled, phase 2a trial. Lancet Respir Med. 2025, 13:47-58. 10.1016\/S2213-2600(24)00324-2","journal-title":"Lancet Respir Med"},{"key":"ref27","doi-asserted-by":"publisher","DOI":"10.1056\/EVIDoa2500012","article-title":"Mepolizumab for COPD with eosinophilic phenotype following hospitalization","volume":"4","author":"Flynn CA","year":"2025","unstructured":"Flynn CA, McAuley HJ, Elneima O, et al.. Mepolizumab for COPD with eosinophilic phenotype following hospitalization. NEJM Evid. 2025, 4:6. 10.1056\/EVIDoa2500012","journal-title":"NEJM Evid"},{"key":"ref28","doi-asserted-by":"publisher","DOI":"10.1002\/jrsm.1058","article-title":"Network meta-analysis, electrical networks and graph theory","volume":"3","author":"R\u00fccker G","year":"2012","unstructured":"R\u00fccker G. Network meta-analysis, electrical networks and graph theory. Res Synth Methods. 2012, 3:312-24. 10.1002\/jrsm.1058","journal-title":"Res Synth Methods"},{"key":"ref29","doi-asserted-by":"publisher","DOI":"10.18637\/jss.v106.i02","article-title":"netmeta: an R package for network meta-analysis using frequentist methods","volume":"106","author":"Balduzzi S","year":"2023","unstructured":"Balduzzi S, R\u00fccker G, Nikolakopoulou A, et al.. netmeta: an R package for network meta-analysis using frequentist methods. J Stat Softw. 2023, 106:1-40. 10.18637\/jss.v106.i02","journal-title":"J Stat Softw"},{"key":"ref30","doi-asserted-by":"publisher","DOI":"10.1186\/s12874-015-0060-8","article-title":"Ranking treatments in frequentist network meta-analysis works without resampling methods","volume":"15","author":"R\u00fccker G","year":"2015","unstructured":"R\u00fccker G, Schwarzer G. Ranking treatments in frequentist network meta-analysis works without resampling methods. BMC Med Res Methodol. 2015, 15:58. 10.1186\/s12874-015-0060-8","journal-title":"BMC Med Res Methodol"},{"key":"ref31","unstructured":"multinma. Bayesian network meta-analysis of individual and aggregate data. R package version 0.8.1. (2026). Accessed: August 20, 2026: https:\/\/zenodo.org\/records\/19660088."},{"key":"ref32","unstructured":"gemtc. network meta-analysis using Bayesian methods. (2015). Accessed: August 20, 2026: https:\/\/cran.r-project.org\/web\/packages\/gemtc\/index.html."},{"key":"ref33","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pmed.1003082","article-title":"CINeMA: an approach for assessing confidence in the results of a network meta-analysis","volume":"17","author":"Nikolakopoulou A","year":"2020","unstructured":"Nikolakopoulou A, Higgins JP, Papakonstantinou T, Chaimani A, Del Giovane C, Egger M, Salanti G. CINeMA: an approach for assessing confidence in the results of a network meta-analysis. PLoS Med. 2020, 17:e1003082. 10.1371\/journal.pmed.1003082","journal-title":"PLoS Med"},{"key":"ref34","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2303951","article-title":"Dupilumab for COPD with type 2 inflammation indicated by eosinophil counts","volume":"389","author":"Bhatt SP","year":"2023","unstructured":"Bhatt SP, Rabe KF, Hanania NA, et al.. Dupilumab for COPD with type 2 inflammation indicated by eosinophil counts. N Engl J Med. 2023, 389:205-14. 10.1056\/NEJMoa2303951","journal-title":"N Engl J Med"},{"key":"ref35","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2401304","article-title":"Dupilumab for COPD with type 2 inflammation indicated by eosinophil counts","volume":"390","author":"Bhatt SP","year":"2024","unstructured":"Bhatt SP, Rabe KF, Hanania NA, et al.. Dupilumab for COPD with type 2 inflammation indicated by eosinophil counts. N Engl J Med. 2024, 390:2274-83. 10.1056\/NEJMoa2401304","journal-title":"N Engl J Med"},{"key":"ref36","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1708208","article-title":"Mepolizumab for eosinophilic chronic obstructive pulmonary disease","volume":"377","author":"Pavord ID","year":"2017","unstructured":"Pavord ID, Chanez P, Criner GJ, et al.. Mepolizumab for eosinophilic chronic obstructive pulmonary disease. N Engl J Med. 2017, 377:1613-29. 10.1056\/NEJMoa1708208","journal-title":"N Engl J Med"},{"key":"ref37","doi-asserted-by":"publisher","DOI":"10.1016\/S2213-2600(21)00167-3","article-title":"Safety and efficacy of itepekimab in patients with moderate-to-severe COPD: a genetic association study and randomised, double-blind, phase 2a trial","volume":"9","author":"Rabe KF","year":"2021","unstructured":"Rabe KF, Celli BR, Wechsler ME, et al.. Safety and efficacy of itepekimab in patients with moderate-to-severe COPD: a genetic association study and randomised, double-blind, phase 2a trial. Lancet Respir Med. 2021, 9:1288-98. 10.1016\/S2213-2600(21)00167-3","journal-title":"Lancet Respir Med"},{"key":"ref38","doi-asserted-by":"publisher","DOI":"10.1016\/S2213-2600(21)00556-7","article-title":"Astegolimab, an anti-ST2, in chronic obstructive pulmonary disease (COPD-ST2OP): a phase 2a, placebo-controlled trial","volume":"10","author":"Yousuf AJ","year":"2022","unstructured":"Yousuf AJ, Samani NJ, Brightling CE, et al.. Astegolimab, an anti-ST2, in chronic obstructive pulmonary disease (COPD-ST2OP): a phase 2a, placebo-controlled trial. Lancet Respir Med. 2022, 10:469-77. 10.1016\/S2213-2600(21)00556-7","journal-title":"Lancet Respir Med"},{"key":"ref39","doi-asserted-by":"publisher","DOI":"10.1016\/S2213-2600(14)70187-0","article-title":"Benralizumab for chronic obstructive pulmonary disease and sputum eosinophilia: a randomised, double-blind, placebo-controlled, phase 2a study","volume":"2","author":"Brightling CE","year":"2014","unstructured":"Brightling CE, Bleecker ER, Panettieri RA Jr, et al.. Benralizumab for chronic obstructive pulmonary disease and sputum eosinophilia: a randomised, double-blind, placebo-controlled, phase 2a study. Lancet Respir Med. 2014, 2:891-901. 10.1016\/S2213-2600(14)70187-0","journal-title":"Lancet Respir Med"},{"key":"ref40","doi-asserted-by":"publisher","DOI":"10.1016\/j.jclinepi.2010.03.016","article-title":"Graphical methods and numerical summaries for presenting results from multiple-treatment meta-analysis: an overview and tutorial","volume":"64","author":"Salanti G","year":"2011","unstructured":"Salanti G, Ades AE, Ioannidis JP. Graphical methods and numerical summaries for presenting results from multiple-treatment meta-analysis: an overview and tutorial. J Clin Epidemiol. 2011, 64:163-71. 10.1016\/j.jclinepi.2010.03.016","journal-title":"J Clin Epidemiol"},{"key":"ref41","doi-asserted-by":"publisher","DOI":"10.1093\/ajrccm\/aamag226","article-title":"Astegolimab for COPD with frequent exacerbations: pooled analysis of the ALIENTO and ARNASA trials","volume":"0","author":"Wedzicha JA","year":"2026","unstructured":"Wedzicha JA, Agust\u00ed \u00c0, Brightling CE, et al.. Astegolimab for COPD with frequent exacerbations: pooled analysis of the ALIENTO and ARNASA trials. Am J Respir Crit Care Med. 2026, 0:aamag226. 10.1093\/ajrccm\/aamag226","journal-title":"Am J Respir Crit Care Med"},{"key":"ref42","doi-asserted-by":"publisher","DOI":"10.2147\/COPD.S504774","article-title":"Efficacy and safety of biologics targeting type 2 inflammation in COPD: a systematic review and network meta-analysis","volume":"20","author":"Li S","year":"2025","unstructured":"Li S, Yi B, Wang H, Xu X, Yu L. Efficacy and safety of biologics targeting type 2 inflammation in COPD: a systematic review and network meta-analysis. Int J Chron Obstruct Pulmon Dis. 2025, 20:2143-59. 10.2147\/COPD.S504774","journal-title":"Int J Chron Obstruct Pulmon Dis"},{"key":"ref43","doi-asserted-by":"publisher","DOI":"10.1080\/15412555.2026.2689394","article-title":"Number needed to treat with biologics in type-2 inflammation COPD: a systematic review and meta-analysis","volume":"23","author":"Wang Q","year":"2026","unstructured":"Wang Q, Ma Q. Number needed to treat with biologics in type-2 inflammation COPD: a systematic review and meta-analysis. COPD. 2026, 23:2689394. 10.1080\/15412555.2026.2689394","journal-title":"COPD"},{"key":"ref44","doi-asserted-by":"publisher","DOI":"10.1016\/j.rmed.2026.108815","article-title":"Biological therapy for chronic obstructive pulmonary disease (COPD): effectiveness and safety","volume":"256","author":"Garc\u00eda Morales OM","year":"2026","unstructured":"Garc\u00eda Morales OM, D\u00edaz L, Auladell-Rispau A, Poloni D, Torres-L\u00f3pez LA, Cuchi GU, Rojas-Reyes MX. Biological therapy for chronic obstructive pulmonary disease (COPD): effectiveness and safety. Respir Med. 2026, 256:108815. 10.1016\/j.rmed.2026.108815","journal-title":"Respir Med"},{"key":"ref45","doi-asserted-by":"publisher","DOI":"10.2147\/COPD.S550144","article-title":"Multi-criteria decision analysis of biologics in chronic obstructive pulmonary disease","volume":"20","author":"Matera MG","year":"2025","unstructured":"Matera MG, Calzetta L, Rogliani P, Cazzola M. Multi-criteria decision analysis of biologics in chronic obstructive pulmonary disease. Int J Chron Obstruct Pulmon Dis. 2025, 20:3163-73. 10.2147\/COPD.S550144","journal-title":"Int J Chron Obstruct Pulmon Dis"},{"key":"ref46","doi-asserted-by":"publisher","DOI":"10.3389\/fmed.2025.1636238","article-title":"Dupilumab for the treatment of COPD: protocol for a systematic review and meta-analysis","volume":"12","author":"Xue B","year":"2025","unstructured":"Xue B, Xiao Q, Huang Y, Wang M. Dupilumab for the treatment of COPD: protocol for a systematic review and meta-analysis. Front Med (Lausanne). 2025, 12:1636238. 10.3389\/fmed.2025.1636238","journal-title":"Front Med (Lausanne)"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/522885-efficacy-and-safety-of-biologic-therapies-targeting-type-2-and-epithelial-alarmin-pathways-in-chronic-obstructive-pulmonary-disease-a-systematic-review-and-network-meta-analysis-of-randomized-controlled-trials","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,28]],"date-time":"2026-08-28T07:57:37Z","timestamp":1787903857000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/522885-efficacy-and-safety-of-biologic-therapies-targeting-type-2-and-epithelial-alarmin-pathways-in-chronic-obstructive-pulmonary-disease-a-systematic-review-and-network-meta-analysis-of-randomized-controlled-trials"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,28]]},"references-count":46,"URL":"https:\/\/doi.org\/10.7759\/cureus.115334","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2026,8,28]]}}}